176 related articles for article (PubMed ID: 22901013)
21. Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA.
Jung Y; Mikata Y; Lippard SJ
J Biol Chem; 2001 Nov; 276(47):43589-96. PubMed ID: 11568187
[TBL] [Abstract][Full Text] [Related]
22. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
McA'Nulty MM; Whitehead JP; Lippard SJ
Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
[TBL] [Abstract][Full Text] [Related]
23. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.
Guggenheim ER; Xu D; Zhang CX; Chang PV; Lippard SJ
Chembiochem; 2009 Jan; 10(1):141-57. PubMed ID: 19053130
[TBL] [Abstract][Full Text] [Related]
24. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
25. The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain.
Mitkova E; Ugrinova I; Pashev IG; Pasheva EA
Biochemistry; 2005 Apr; 44(15):5893-8. PubMed ID: 15823048
[TBL] [Abstract][Full Text] [Related]
26. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link on the conformational and thermodynamic properties of duplex DNA.
Pilch DS; Dunham SU; Jamieson ER; Lippard SJ; Breslauer KJ
J Mol Biol; 2000 Feb; 296(3):803-12. PubMed ID: 10677282
[TBL] [Abstract][Full Text] [Related]
27. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization.
Suo Z; Lippard SJ; Johnson KA
Biochemistry; 1999 Jan; 38(2):715-26. PubMed ID: 9888812
[TBL] [Abstract][Full Text] [Related]
28. Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro.
Patrick SM; Turchi JJ
Biochemistry; 1998 Jun; 37(24):8808-15. PubMed ID: 9628743
[TBL] [Abstract][Full Text] [Related]
29. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II).
Corda Y; Anin MF; Leng M; Job D
Biochemistry; 1992 Feb; 31(7):1904-8. PubMed ID: 1536834
[TBL] [Abstract][Full Text] [Related]
30. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA.
Jamieson ER; Lippard SJ
Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248
[TBL] [Abstract][Full Text] [Related]
31. HMGB proteins: interactions with DNA and chromatin.
Stros M
Biochim Biophys Acta; 2010; 1799(1-2):101-13. PubMed ID: 20123072
[TBL] [Abstract][Full Text] [Related]
32. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
[TBL] [Abstract][Full Text] [Related]
33. DNA bending and unwinding due to the major 1,2-GG intrastrand cross-link formed by antitumor cis-diamminedichloroplatinum(II) are flanking-base independent.
Stehlikova K; Kostrhunova H; Kasparkova J; Brabec V
Nucleic Acids Res; 2002 Jul; 30(13):2894-8. PubMed ID: 12087174
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
[TBL] [Abstract][Full Text] [Related]
35. A single d(GpG) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor.
Massaad-Massade L; Massaad C; Legendre F; Bas V; Chottard J; Beaune P; Barouki R
FEBS Lett; 2000 Jan; 466(1):49-53. PubMed ID: 10648810
[TBL] [Abstract][Full Text] [Related]
36. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins.
Wei M; Cohen SM; Silverman AP; Lippard SJ
J Biol Chem; 2001 Oct; 276(42):38774-80. PubMed ID: 11514569
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
Turchi JJ; Li M; Henkels KM
Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
[TBL] [Abstract][Full Text] [Related]
38. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.
Gelasco A; Lippard SJ
Biochemistry; 1998 Jun; 37(26):9230-9. PubMed ID: 9649303
[TBL] [Abstract][Full Text] [Related]
39. Testis-specific HMG-domain protein alters the responses of cells to cisplatin.
Zamble DB; Mikata Y; Eng CH; Sandman KE; Lippard SJ
J Inorg Biochem; 2002 Aug; 91(3):451-62. PubMed ID: 12175937
[TBL] [Abstract][Full Text] [Related]
40. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
Kane SA; Lippard SJ
Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
